- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04950634
Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Sexual Dimorphism in the Prevalence and Progression of Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Sex might interact with cardioautonomic neuropathy (CAN) in the development of macrovascular disease in patients with type 1 diabetes (T1D). The regulation of the autonomic system shows sexual dimorphism, and may contribute to the cardiovascular risk overload in women with T1D.
The aims of this project are:
A.1) Determining the prevalence of CAN and subclinical atherosclerosis in a large cohort of consecutive patients with T1D as a function of sex (cross-sectional study).
A.2.) Addressing the progression of CAN and subclinical atherosclerosis in patients with T1D as a function of sex (longitudinal prospective study).
A.3.) Investigating the influence of sex steroids and circulating biomarkers in the development and progression of CAN and subclinical atherosclerosis.
Research designs:
A cross-sectional design/prevalence screening study determining the prevalence of CAN as a function of sex in 320 consecutive individuals with DM1.
A longitudinal prospective study: the cohort of prevalence screening study will be prospectively followed, and the assessment of cardiovascular autonomic function and subclinical atherosclerosis will be repeated over time.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28034
- Lía Nattero Chávez
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of type 1 diabetes mellitus, as defined by ADA criteria
Exclusion Criteria:
- Renal transplantation or renal replacement therapy;
- prior diagnosis of macrovascular disease (CHD, cerebrovascular disease, carotid disease, PAD, or atherosclerotic aortic aneurism);
- ongoing pregnancy;
- diagnosis of types of diabetes mellitus other than type 1;
- diagnosis of types of neuropathy other than diabetic neuropathy.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To address sexual dimorphism in the prevalence of CAN in patients with T1D.
Time Frame: Two years
|
Blood pressure (mmHg) to active standing and Ewing and Clarke tests.
|
Two years
|
|
To address sexual dimorphism in the prevalence of CAN in patients with T1D.
Time Frame: Two years
|
Heart rate responses (bpm) to active standing and Ewing and Clarke tests.
|
Two years
|
|
To address sexual dimorphism in subclinical atherosclerosis in patients with T1D.
Time Frame: Two years
|
Mean carotid intima-media thickness (mm)
|
Two years
|
|
To assess the role of sex on the progression of cardiovascular dysautonomy in patients with T1D.
Time Frame: Four years
|
Blood pressure (mmHg) to active standing and Ewing and Clarke tests.
|
Four years
|
|
To assess the role of sex on the progression of cardiovascular dysautonomy in patients with T1D.
Time Frame: Four years
|
Heart rate responses (bpm) to active standing and Ewing and Clarke tests.
|
Four years
|
|
To assess the role of sex on the progression of subclinical atherosclerosis in patients with T1D.
Time Frame: Four years
|
Mean carotid intima-media thickness (mm)
|
Four years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To identify the influence of sex steroids on the evolution of cardiac autonomic dysfunction.
Time Frame: Four years
|
Heart rate responses (bpm) to active standing and Ewing and Clarke tests.
|
Four years
|
|
To identify the influence of sex steroids on the evolution of cardiac autonomic dysfunction.
Time Frame: Four years
|
Blood pressure (mmHg) to active standing and Ewing and Clarke tests.
|
Four years
|
|
To identify the influence of sex steroids on the evolution of subclinical atherosclerosis
Time Frame: Four years
|
Mean carotid intima-media thickness (mm)
|
Four years
|
|
To identify novel circulating markers of CAN
Time Frame: Four years
|
Heart rate responses (bpm) to active standing and Ewing and Clarke tests.
|
Four years
|
|
To identify novel circulating markers of CAN
Time Frame: Four years
|
Blood pressure (mmHg) to active standing and Ewing and Clarke tests.
|
Four years
|
|
To identify novel circulating markers of subclinical atherosclerosis
Time Frame: Four years
|
Mean carotid intima-media thickness (mm)
|
Four years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Nattero-Chavez L, Alonso Diaz S, Jimenez-Mendiguchia L, Garcia-Cano A, Fernandez-Duran E, Dorado Avendano B, Escobar-Morreale HF, Luque-Ramirez M. Sexual Dimorphism and Sex Steroids Influence Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes. Diabetes Care. 2019 Nov;42(11):e175-e178. doi: 10.2337/dc19-1375. Epub 2019 Sep 17. No abstract available.
- Nattero-Chavez L, Insenser M, Amigo N, Samino S, Martinez-Micaelo N, Dorado Avendano B, Quintero Tobar A, Escobar-Morreale HF, Luque-Ramirez M. Quantification of lipoproteins by proton nuclear magnetic resonance spectroscopy (1H-NMRS) improves the prediction of cardiac autonomic dysfunction in patients with type 1 diabetes. J Endocrinol Invest. 2024 Aug;47(8):2075-2085. doi: 10.1007/s40618-023-02289-9. Epub 2024 Jan 6.
- Insenser MR, Nattero-Chavez L, Luque-Ramirez M, Quinones SL, Quintero-Tobar A, Samino S, Amigo N, Dorado Avendano B, Fiers T, Escobar-Morreale HF. Investigating the Link between Intermediate Metabolism, Sexual Dimorphism, and Cardiac Autonomic Dysfunction in Patients with Type 1 Diabetes. Metabolites. 2024 Aug 6;14(8):436. doi: 10.3390/metabo14080436.
- Nattero-Chavez L, Insenser M, Quintero Tobar A, Fernandez-Duran E, Dorado Avendano B, Fiers T, Kaufman JM, Luque-Ramirez M, Escobar-Morreale HF. Sex differences and sex steroids influence on the presentation and severity of cardiovascular autonomic neuropathy of patients with type 1 diabetes. Cardiovasc Diabetol. 2023 Feb 15;22(1):32. doi: 10.1186/s12933-023-01766-y.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 189/17
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.